Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease (ENRICH)

Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease (ENRICH): A Randomized Controlled Trial

The use of contrast media (CM) poses a risk of post-contrast acute kidney injury (PC-AKI), especially among patients chronic kidney disease (CKD). International guidelines recommend intravenous (IV) hydration with isotonic 0.9% NaCl for three-four hours pre-contrast and four-six hours post-contrast. Recent studies have proven that oral hydration or no hydration is non-inferior to IV hydration in patients with mild to moderate CKD (eGFR 30-60 mL/min/1.73 m2). However, no randomized controlled trials have evaluated alternative hydration methods against the guideline-recommended hydration protocol for the prevention of PC-AKI in high-risk patients with severe CKD (eGFR < 30 mL/min/1.73 m2).

Thus, the main focus of this trial is to evaluate IV hydration vs. oral hydration for their efficacy to prevent of PC-AKI in patients with severe CKD, who are scheduled for an elective contrast-enhanced CT-scan (CECT) with IV contrast-administration.

Our research hypotheses consist of the following:

1. Oral hydration with bottled tap water is non-inferior to IV-hydration with isotonic 0.9% NaCl as renal prophylaxis to prevent PC-AKI in patients with severe CKD referred for an elective IV CECT.
2. NGAL and cfDNA are early and precise plasma and urinary biomarkers of PC-AKI with excellent diagnostic and prognostic accuracy for PC-AKI, dialysis, renal adverse events, hospitalization, progression in CKD-symptoms, and all-cause mortality.

Study Overview

• Status: Recruiting
• Conditions: Kidney Failure, Chronic; Kidney Injury; Risk Reduction; Contrast-induced Nephropathy
• Intervention / Treatment: Other: Preventive treatment with IV-hydration; Other: Preventive treatment with oral hydration

Detailed Description

Trial design:

This study is a pragmatic investigator-iniated, single-centre, open-labelled, parallel-group non-inferiority randomized controlled trial with two parallel arms. Patients will randomly be allocated to preventive treatment with IV hydration or oral hydration.

Participants and study setting:

The ENRICH-trial is conducted at Odense University Hospital (OUH), which is a tertiary health-care centre. The referral area covers the region of Southern Denmark, which corresponds to 1.25 million citizens in 22 municipalities of both urban and rural environment. The trial enrols high-risk patients with an eGFR < 30 mL/min/1.73 m2 scheduled for IV CECT using approximately 50-150 mL of CM (GE Healthcare, Omnipaque 500 mL, osmolality 350 mg I/mL).

The study population will consist of patients, who are referred for an elective IV CECT in the work-up for treatment of CVD (e.g., transaortic valve-implantation, ablation, endocarditis etc.) or suspected CVD (e.g., angina etc.), suspected cancer, thoracic/abdominal/urogenital diseases, or cardiovascular work-up before kidney transplantation. Patients referred for an acute or subacute IV CECT with competing etiologies for PC-AKI (e.g., sepsis, acute tubular necrosis, cardiogenic shock etc.) will not be considered eligible for inclusion.

Randomization:

The randomized allocation to preventive treatment with either IV-hydration or oral hydration will be performed in REDCap, which is computer-based tool provided by our collaborator, Open Patient data Explorative Network (OPEN). The randomization sequence list is generated and implemented in the computer-based randomization tool by our data manager and will remain unknown throughout the study period.

The randomization will be performed as 2-4-2 block randomization with stratification for DM-status, CKD-stage (eGFR < 15 mL/min/1.73 m2 or 15-29 mL/min/1.73 m2), and the basis of referral for IV CECT (kidney transplantation or other diseases). Participants are then followed for a 30-day period with standard blood testing for kidney function at two-five days after IV CECT and a 30-day follow-up for the key secondary outcomes.

Definition of PC-AKI:

PC-AKI is defined in accordance with the KDIGO-guidelines, which is a relative increase in serum creatinine (SCr) > 50% from baseline or an absolute increase of SCr > 0.3 mg/dL from baseline.

Course of action:

High-risk patients with severe CKD (eGFR < 30 mL/min/1.73 m2) and a scheduled IV CECT will be considered for eligibility. Eligible patients will be screened according to the study's inclusion/exclusion criteria. Eligibility is assessed from the patient's electronic health record (EHR), which contains data regarding health status and recent test results for evaluation of renal function.

Eligible patients will be presented to the guideline-recommendations for preventive treatment with IV hydration along with blood sampling for evaluation of their renal function < seven days prior to the IV CECT at the time of the scheduling of their IV CECT, according to normal routine at Odense University Hospital. Furthermore, the patients will be presented with a short introduction to this study. If the patient is interested, he/she will be contacted by the lead investigators, after which a verbal consent to participate in the study is obtained (approximately seven to 14 days prior to the scheduled IV CECT).

After the verbal consent is given, the guideline-required evaluation of renal function < seven days prior to their IV CECT will be planned along with an additional blood sample to evaluate the renal function one-three days prior to their IV CECT. Furthermore, blood samples to evaluate renal function will be planned at two-three days, four-five days, and 30 days after IV CECT along with follow-up consultations four-five days and 30 days after IV CECT.

A thorough presentation of the study-information will be given by one of the lead investigators at baseline, while the patient has been informed about the possibility of bringing an assessor of their choice. The information will be delivered in a quiet room, which is solely used to deliver patient information. The lead investigators will make sure that the presentation is given within a reasonable timeframe prior to their scheduled IV CECT.

During the presentation of the study the patient will be informed of the purpose of the study and the written patient information will be sent via e-mail or physically handed to the patient if desired. Patients will be given as much time as wanted to decide if they wish to participate in the study after the oral information has been given. Patients will be offered the possibility to call or physically meet with one of the lead investigators in case of additional questions before signing the informed consent.

Subjects can leave the study at any time for any reason if they wish to do so without any clinical consequences. Signed informed consent will be provided prior to any research procedures. A subject is considered enrolled in the study once the subject is randomized.

Patient data from EHR will be obtained according to the REDCap-database and the study endpoints after the verbal consent is delivered.

Participant retention, follow-up, and withdrawal:

Once a patient is enrolled and randomized, the research group will make every reasonable effort to follow the patient for the entire study period. If the patient fails to attend their appointment for blood sampling to evaluate renal function, the patient will be contacted by telephone, and a new appointment for blood sampling is scheduled within the next 24 hours. The patient will only be excluded from the study after randomization if the patient does not receive the preventive treatment according to the randomization or if the IV CECT is cancelled after randomization and preventive treatment. The rate of loss-to-follow-up for the primary and secondary outcomes are expected to be < 10%.

Variables:

Standard blood parameters to evaluate renal function will be obtained < 90 days, < seven days, one-three days, and at baseline prior to the scheduled IV CECT. Furthermore, an urine sample for albumine/creatinine ratio (mg/g) will be obtained at baseline before CM exposure. The standard blood parameters will also be obtained two-three days and/or four-five days, and 25-40 days after the scheduled IV CECT. Additional blood sampling to evaluate renal function will be performed at seven days and/or 14-21 days after IV CECT if the patient has increasing SCr four-five days after IV CECT consistent with PC-AKI.

The standard blood parameters for patients referred for IV CECT consist of the following: Hemoglobin (mM), erythrocytes (count/L), SCr (μmol/L), eGFR (mL/min/1.73 m2), albumine (μmol/L), sodium (mM), and potassium (mM).

The prospective cohort is followed over a 30-day period for events of dialysis treatment, renal adverse events, hospitalization due to hydration- or contrast-related sequelae (i.e., symptomatic heart failure, arrythmias, renal insufficiency, hyponatremia or hypernatremia), and all-cause mortality.

Progression in CKD-symptoms will be obtained from registration of uremic symptoms through a medical interview at baseline and ≤ 30 days after IV CECT. A trained interviewer will identify any clinical signs of progression in CKD within the 30-day follow-up. Progression in CKD is defined as progression in uremic symptoms, which consist of the following:

- Weight loss, loss of appetite, cramps, nausea, vomiting, pruritus, bruising, fatigue, peripheral edema, impaired consciousness, and changes in sense of taste.

The medical history, medicine use, and echocardiography will be obtained at baseline before initiation of the hydration protocol. The patient will then tend to their IV CECT.

Blood- and urine samples for biomarkers of PC-AKI will be collected before IV CECT and three-four hours after IV CECT.

The admission time is defined as the timespan between the start and the completion of the preventive treatment, which is registered as 'date-month-year-hours-minutes'.

Dates and reasons for hospital admission < 90 days before IV CECT will also be registered along with additional contrast exposure within the 30-day follow-up period after the scheduled IV CECT.

The following parameters will also be obtained for the subgroup of participants, who are referred for a cardiac IV CECT:

• Estimated coronary artery calcification score (CAC-score).
• Stenosis > 50% of the left main coronary artery (LM).
• The grade of stenosis will be analyzed if present in the coronary arteries; LM, left anterior descending artery (LAD), left circumflex artery (LCx), and right coronary artery (RCA).
• Aortic valve calcification (AVC) and mitral annulus calcification (MAC).
• Calcification (Agatson-score) of the aorta (aorta ascendens, arcus aorta, and aorta descendens), the suprarenal and infrarenal aorta, and the renal arteries.
• The diameter of aorta (aorta ascendens, arcus aorta, aorta descendens) and iliac arteries.
• The size of the left atrium (cm2).

Safety:

An interim analysis will be performed after inclusion of 127 patients to evaluate the primary outcomes and the key secondary outcomes. The steering committee will consider terminating the study preliminary if the analyses conclude a significant difference in the incidence of the primary and/or the key secondary outcomes between the two groups.

• Study Type: Interventional
• Enrollment (Estimated): 254
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Kristian Altern Øvrehus, Chief Physician; Phone Number: +45 28305454; Email: kristian.altern.ovrehus@rsyd.dk
• Study Contact Backup: Name: Emil Johannes Ravn, BSc.Med.; Phone Number: +45 31476794; Email: emil.johannes.ravn2@rsyd.dk

Study Locations

• Denmark
  • Fyn
    • Odense C, Fyn, Denmark, 5000
      • Recruiting
      • Department of cardiology
      • Contact: Kristian Altern Øvrehus, Chief Physician; Phone Number: +45 28305454; Email: kristian.altern.ovrehus@rsyd.dk
      • Contact: Emil Johannes Ravn, BSc.Med.; Phone Number: +45 31476794; Email: emil.johannes.ravn2@rsyd.dk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• eGFR < 30 mL/min/1.73 m2
• Scheduled for elective IV CECT
• Age ≥ 18
• Signed informed consent

Exclusion Criteria:

• Allergy to Iodine
• Pregnancy
• Active dialysis treatment
• Acute infectious or inflammatory disease
• Acute pre- and/or post-renal kidney failure
• Unable to understand study information

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: IV-hydration group (standard of care according to international guidelines); The IV-hydration with isotonic 0.9% NaCl will be initiated three hours prior to the IV CECT and completed four hours after IV CECT (infusion rate of 1-3 mL/kg/hour). Patients are prescribed a fixed volume of 1000 mL, which is equally distributed before and after IV CECT (500 mL before and 500 mL after). Patients with heart failure (LVEF ≤ 40%) are prescribed a reduced volume of 500 mL, which is also equally distributed before and after IV CECT (250 mL before and 250 mL after).	Other: Preventive treatment with IV-hydration; IV hydration with isotonic 0.9% NaCl
Active Comparator: Oral hydration group; The oral hydration regimen will be initiated one-two hours prior to IV CECT and completed within four hours after IV CECT. Patients are prescribed a fixed volume of 1000 mL, which is distributed equally before and after IV CECT (500 mL before and 500 mL after). Patients with heart failure (LVEF ≤ 40%) are prescribed a reduced volume of 500 mL, which is equally distributed before and after IV CECT (250 mL before and 250 mL after).	Other: Preventive treatment with oral hydration; Oral hydration with regular bottled water

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of PC-AKI	The incidence of PC-AKI within the two arms	2-5 days after IV CECT

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of new onset need for dialysis treatment	The incidence of patients with incident need for dialysis treatment, which is registered from the EHR and/or telephone consultation	≤ 30 days after IV CECT
Renal adverse events	The incidence of renal adverse events defined as a relative increase in SCr > 15% and/or a decrease in eGFR > 15% and/or progression in CKD-stage from CKD-stage IV to CKD-stage Va	25-40 days after IV CECT
Hospitalization due to symptomatic heart failure	The incidence of patients hospitalized due to symptomatic heart failure, which is registered from the EHR and/or telephone consultation	≤ 30 days after IV CECT
All-cause mortality	All-cause mortality, which is registered from the EHR	≤ 30 days after IV CECT
Hospitalization due to suspected hydration- or contrast-related sequelae	Hospitalization due to suspected hydration- or contrast-related sequelae (e.g., arrythmias, renal insufficiency, hyponatremia or hypernatremia), which is registered from the EHR and/or telephone consultation	≤ 30 days after IV CECT
Progression in CKD-symptoms	Progression in CKD-symptoms within 30 days after IV CECT defined as an increase in number of uremic symptoms compared to number of uremic at baseline within the two arms (see definition of "uremic symptoms" under "Variables" in the detailed description of the trial)	≤ 30 days after IV CECT
Incidence of PC-AKI based on the criteria from the previously used and most cited definition of PC-AKI	The incidence of PC-AKI within the population and the two arms defined as a relative increase in SCr > 25% from baseline or an absolute increase > 0.5 mg/dL	2-5 days after IV CECT
Timepoints of diagnosis for PC-AKI	The difference in PC-AKI diagnosed two-three days after IV CECT and four-five days after IV CECT within the population and the two arms	2-5 days after IV CECT
Number of patients with normalization of PC-AKI	Number of participants with normalization of PC-AKI within study population and the two arms defined as a decline in SCr below the criteria for PC-AKI	≤ 40 days after IV CECT
Mean changes in SCr	Mean changes in SCr from baseline at different timepoints within the study population and the two arms	SCr is measured on the following time-points (days from baseline): -89 to -seven days, -six to -four days, -three to -one days, 0 days (baseline), +two to three days, +four to five days, and +25 to +40 days
Mean changes in eGFR.	Mean changes in eGFR from baseline at different timepoints within the study population and the two arms	eGFR is measured on the following time-points (days from baseline): -89 to -seven days, -six to -four days, -three to -one days, 0 days (baseline), +two to three days, +four to five days, and +25 to +40 days
The effect of hydration on standard blood parameters	Mean changes in standard blood parameters within the two arms. Standard blood parameters are the following: Hemoglobin (mM), erythrocytes (count/L), SCr (micromole/L), eGFR (mL/min/1.73 m2), albumine (micromole/L), sodium (mM), and potassium (mM)	Standard blood parameters will be obtained after IV CECT at +two to three days and/or +four to five days, and +25 to +40 days from baseline
Mean values of plasma and urinary NGAL and cell-free DNA	Mean values of plasma and urinary NGAL (μg/mg) and cell-free DNA (ng/mg) at baseline and 4 hours after IV CECT	In-hospital: Before initiation of the hydration protocol and the IV CECT (baseline) and 4 hours after IV CECT
Mean changes of plasma and urinary NGAL and cell-free DNA	Mean changes in plasma and urinary NGAL (μg/mg) and cell-free DNA (ng/mg) from baseline (0 hours) to four hours after IV CECT	In-hospital: Before initiation of the hydration protocol and the IV CECT (baseline) and 4 hours after IV CECT
The diagnostic and prognostic accuracy of plasma and urinary NGAL and cell-free DNA	Sensitivities, specificities, negative predictive values, positive predictive values, negative likelihood-ratios, and positive likelihood-ratios of plasma and urinary NGAL (μg/mg) and cell-free DNA (ng/mg) based on the most optimal cut-off point for each biomarker based on Receiver Operating Characteristics-Curves (ROC-curves) and their corresponding Area Under Curve (AUC). The most optimal cut-off is defined as the closest point on the ROC-curves, at which the sensitivity = specificity = 1.0	In-hospital: Before initiation of the hydration protocol and the IV CECT (baseline) and 4 hours after IV CECT
The diagnostic and prognostic accuracy of plasma and urinary NGAL and cell-free DNA	Assesment of the most optimal cut-off point for each biomarker based on Receiver Operating Characteristics-Curves (ROC-curves) and their corresponding Area Under Curve (AUC). The most optimal cut-off is defined as the closest point on the ROC-curves, at which the sensitivity = specificity = 1.0	In-hospital: Before initiation of the hydration protocol and the IV CECT (baseline) and 4 hours after IV CECT
The diagnostic and prognostic accuracy of plasma and urinary NGAL and cell-free DNA	The correlation between SCr and plasma and urinary NGAL (μg/mg) and cell-free DNA (ng/mg) will be illustrated in Scatter Plots.	In-hospital: Before initiation of the hydration protocol and the IV CECT (baseline) and 4 hours after IV CECT
Cost-effectiveness	The use of resources (presented in DKK, EUR, and USD) for IV-hydration and oral hydration within the two arms are calculated from the following parameters: The cost of occupying a hospital bed per hour (nursing, staff salaries etc.), IV-drip, and hydration bags with saline or bottled tap water.	1 day (at the day of the patient's scheduled cardiac CT)
Time-effectiveness of the two hydration protocols.	The two hydration methods are compared for the amount of time (hours and minutes) from initiation to completion hydration protocols.	In-hospital: Starting 1-3 hours before IV CECT and lasting maximally until 4 hours after IV CECT
Risk of PC-AKI according to the size of the kidneys	The size of the right and left kidney will be measured and indexed to the body-size of the patient and analyzed as a risk factor for the occurence of PC-AKI	2-5 days after IV CECT

Collaborators and Investigators

• Sponsor: Odense University Hospital
• Collaborators: Novo Nordisk A/S; Department of Nephrology, Odense University Hospital; The A.P. Moller Foundation; The Research Counsil of Odense University Hospital; Copenhagen University's Research Foundation for Medical Students; Department of Clinical Genetics, Odense University Hospital; Helen and Ejnar Bjørnow's Foundation; Sophus Jacobsen and Astrid Jacobsen's Foundation; Open Patient data Explorative Network (OPEN)

Publications and helpful links

General Publications

• Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005 Nov;16(11):3365-70. doi: 10.1681/ASN.2004090740. Epub 2005 Sep 21.
• Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013 Jul 20;382(9888):260-72. doi: 10.1016/S0140-6736(13)60687-X. Epub 2013 May 31. Erratum In: Lancet. 2013 Jul 20;382(9888):208.
• McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, Mehta A. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol. 2016 Sep 27;68(13):1465-1473. doi: 10.1016/j.jacc.2016.05.099.
• Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002 May 14;105(19):2259-64. doi: 10.1161/01.cir.0000016043.87291.33.
• Merkle J, Daka A, Deppe AC, Wahlers T, Paunel-Gorgulu A. High levels of cell-free DNA accurately predict late acute kidney injury in patients after cardiac surgery. PLoS One. 2019 Jun 18;14(6):e0218548. doi: 10.1371/journal.pone.0218548. eCollection 2019.
• Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A; NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009 Dec;54(6):1012-24. doi: 10.1053/j.ajkd.2009.07.020. Epub 2009 Oct 21.
• Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, Ommen VV, Wildberger JE. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017 Apr 1;389(10076):1312-1322. doi: 10.1016/S0140-6736(17)30057-0. Epub 2017 Feb 21.
• Christiansen C. X-ray contrast media--an overview. Toxicology. 2005 Apr 15;209(2):185-7. doi: 10.1016/j.tox.2004.12.020.
• van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin MF, Bertolotto M, Clement O, Heinz-Peer G, Stacul F, Webb JAW, Thomsen HS. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018 Jul;28(7):2856-2869. doi: 10.1007/s00330-017-5247-4. Epub 2018 Feb 7.
• Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006 Apr;(100):S11-5. doi: 10.1038/sj.ki.5000368.
• Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019 May 30;380(22):2146-2155. doi: 10.1056/NEJMra1805256. No abstract available.
• McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, Tumlin J; CIN Consensus Working Panel. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006 Sep 18;98(6A):27K-36K. doi: 10.1016/j.amjcard.2006.01.022. Epub 2006 Feb 23.
• Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020 Mar;294(3):660-668. doi: 10.1148/radiol.2019192094. Epub 2020 Jan 21.
• McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008 Apr 15;51(15):1419-28. doi: 10.1016/j.jacc.2007.12.035. Erratum In: J Am Coll Cardiol.2008 Jun 3;51(22): 2197.
• Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002 May;39(5):930-6. doi: 10.1053/ajkd.2002.32766.
• McDonald JS, McDonald RJ, Comin J, Williamson EE, Katzberg RW, Murad MH, Kallmes DF. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology. 2013 Apr;267(1):119-28. doi: 10.1148/radiol.12121460. Epub 2013 Jan 14.
• Geenen RW, Kingma HJ, van der Molen AJ. Contrast-induced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging. 2013 Dec;4(6):811-20. doi: 10.1007/s13244-013-0291-3. Epub 2013 Oct 3.
• Seibert FS, Heringhaus A, Pagonas N, Rudolf H, Rohn B, Bauer F, Timmesfeld N, Trappe HJ, Babel N, Westhoff TH. Biomarkers in the prediction of contrast media induced nephropathy - the BITCOIN study. PLoS One. 2020 Jul 16;15(7):e0234921. doi: 10.1371/journal.pone.0234921. eCollection 2020.
• Filiopoulos V, Biblaki D, Vlassopoulos D. Neutrophil gelatinase-associated lipocalin (NGAL): a promising biomarker of contrast-induced nephropathy after computed tomography. Ren Fail. 2014 Jul;36(6):979-86. doi: 10.3109/0886022X.2014.900429. Epub 2014 Mar 27.
• Lacquaniti A, Buemi F, Lupica R, Giardina C, Mure G, Arena A, Visalli C, Baldari S, Aloisi C, Buemi M. Can neutrophil gelatinase-associated lipocalin help depict early contrast material-induced nephropathy? Radiology. 2013 Apr;267(1):86-93. doi: 10.1148/radiol.12120578. Epub 2013 Jan 7.
• Coimbra S, Rocha S, Nascimento H, Valente MJ, Catarino C, Rocha-Pereira P, Sameiro-Faria M, Oliveira JG, Madureira J, Fernandes JC, Miranda V, Belo L, Bronze-da-Rocha E, Santos-Silva A. Cell-free DNA as a marker for the outcome of end-stage renal disease patients on haemodialysis. Clin Kidney J. 2020 Aug 24;14(5):1371-1378. doi: 10.1093/ckj/sfaa115. eCollection 2021 May.
• Celec P, Vlkova B, Laukova L, Babickova J, Boor P. Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases. Expert Rev Mol Med. 2018 Jan 18;20:e1. doi: 10.1017/erm.2017.12.
• Zhang W, Zhang J, Yang B, Wu K, Lin H, Wang Y, Zhou L, Wang H, Zeng C, Chen X, Wang Z, Zhu J, Songming C. Effectiveness of oral hydration in preventing contrast-induced acute kidney injury in patients undergoing coronary angiography or intervention: a pairwise and network meta-analysis. Coron Artery Dis. 2018 Jun;29(4):286-293. doi: 10.1097/MCA.0000000000000607.
• Dussol B, Morange S, Loundoun A, Auquier P, Berland Y. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant. 2006 Aug;21(8):2120-6. doi: 10.1093/ndt/gfl133. Epub 2006 Apr 12.
• Sebastia C, Paez-Carpio A, Guillen E, Pano B, Garcia-Cinca D, Poch E, Oleaga L, Nicolau C. Oral hydration compared to intravenous hydration in the prevention of post-contrast acute kidney injury in patients with chronic kidney disease stage IIIb: A phase III non-inferiority study (NICIR study). Eur J Radiol. 2021 Mar;136:109509. doi: 10.1016/j.ejrad.2020.109509. Epub 2021 Jan 14.
• Timal RJ, Kooiman J, Sijpkens YWJ, de Vries JPM, Verberk-Jonkers IJAM, Brulez HFH, van Buren M, van der Molen AJ, Cannegieter SC, Putter H, van den Hout WB, Jukema JW, Rabelink TJ, Huisman MV. Effect of No Prehydration vs Sodium Bicarbonate Prehydration Prior to Contrast-Enhanced Computed Tomography in the Prevention of Postcontrast Acute Kidney Injury in Adults With Chronic Kidney Disease: The Kompas Randomized Clinical Trial. JAMA Intern Med. 2020 Apr 1;180(4):533-541. doi: 10.1001/jamainternmed.2019.7428.
• Agarwal SK, Mohareb S, Patel A, Yacoub R, DiNicolantonio JJ, Konstantinidis I, Pathak A, Fnu S, Annapureddy N, Simoes PK, Kamat S, El-Hayek G, Prasad R, Kumbala D, Nascimento RM, Reilly JP, Nadkarni GN, Benjo AM. Systematic oral hydration with water is similar to parenteral hydration for prevention of contrast-induced nephropathy: an updated meta-analysis of randomised clinical data. Open Heart. 2015 Oct 5;2(1):e000317. doi: 10.1136/openhrt-2015-000317. eCollection 2015.
• Cheungpasitporn W, Thongprayoon C, Brabec BA, Edmonds PJ, O'Corragain OA, Erickson SB. Oral hydration for prevention of contrast-induced acute kidney injury in elective radiological procedures: a systematic review and meta-analysis of randomized controlled trials. N Am J Med Sci. 2014 Dec;6(12):618-24. doi: 10.4103/1947-2714.147977.
• Dong M, Jiao Z, Liu T, Guo F, Li G. Effect of administration route on the renal safety of contrast agents: a meta-analysis of randomized controlled trials. J Nephrol. 2012 May-Jun;25(3):290-301. doi: 10.5301/jn.5000067.
• Yoshikawa D, Isobe S, Sato K, Ohashi T, Fujiwara Y, Ohyama H, Ishii H, Murohara T. Importance of oral fluid intake after coronary computed tomography angiography: an observational study. Eur J Radiol. 2011 Jan;77(1):118-22. doi: 10.1016/j.ejrad.2009.07.011. Epub 2009 Aug 19.
• Kift RL, Messenger MP, Wind TC, Hepburn S, Wilson M, Thompson D, Smith MW, Sturgeon C, Lewington AJ, Selby PJ, Banks RE. A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine. Ann Clin Biochem. 2013 May;50(Pt 3):236-44. doi: 10.1258/acb.2012.012117.
• Magnusson NE, Hornum M, Jorgensen KA, Hansen JM, Bistrup C, Feldt-Rasmussen B, Flyvbjerg A. Plasma neutrophil gelatinase associated lipocalin (NGAL) is associated with kidney function in uraemic patients before and after kidney transplantation. BMC Nephrol. 2012 Feb 10;13:8. doi: 10.1186/1471-2369-13-8.
• Aycock RD, Westafer LM, Boxen JL, Majlesi N, Schoenfeld EM, Bannuru RR. Acute Kidney Injury After Computed Tomography: A Meta-analysis. Ann Emerg Med. 2018 Jan;71(1):44-53.e4. doi: 10.1016/j.annemergmed.2017.06.041. Epub 2017 Aug 12.
• Hiremath S, Akbari A, Shabana W, Fergusson DA, Knoll GA. Prevention of contrast-induced acute kidney injury: is simple oral hydration similar to intravenous? A systematic review of the evidence. PLoS One. 2013;8(3):e60009. doi: 10.1371/journal.pone.0060009. Epub 2013 Mar 26.
• Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material. Radiology. 2013 Apr;267(1):94-105. doi: 10.1148/radiol.12121394. Epub 2013 Jan 29.
• McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology. 2014 Apr;271(1):65-73. doi: 10.1148/radiol.13130775. Epub 2014 Jan 16.
• van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin MF, Bertolotto M, Clement O, Heinz-Peer G, Stacul F, Webb JAW, Thomsen HS. Post-contrast acute kidney injury - Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018 Jul;28(7):2845-2855. doi: 10.1007/s00330-017-5246-5. Epub 2018 Feb 9.
• Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology. 2010 Jul;256(1):21-8. doi: 10.1148/radiol.10092000. No abstract available.
• Solomon R. Contrast-induced acute kidney injury: is there a risk after intravenous contrast? Clin J Am Soc Nephrol. 2008 Sep;3(5):1242-3. doi: 10.2215/CJN.03470708. Epub 2008 Aug 13. No abstract available.
• Ellis JH, Cohan RH. Reducing the risk of contrast-induced nephropathy: a perspective on the controversies. AJR Am J Roentgenol. 2009 Jun;192(6):1544-9. doi: 10.2214/AJR.09.2368.
• Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology. 2006 May;239(2):392-7. doi: 10.1148/radiol.2392050413. Epub 2006 Mar 16.
• McDonald JS, McDonald RJ, Lieske JC, Carter RE, Katzberg RW, Williamson EE, Kallmes DF. Risk of Acute Kidney Injury, Dialysis, and Mortality in Patients With Chronic Kidney Disease After Intravenous Contrast Material Exposure. Mayo Clin Proc. 2015 Aug;90(8):1046-53. doi: 10.1016/j.mayocp.2015.05.016. Erratum In: Mayo Clin Proc. 2015 Oct;90(10):1457. Kallmes, David E [Corrected to Kallmes, David F].
• James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, Knudtson ML, Pannu N, Hemmelgarn BR. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2013 Feb;6(1):37-43. doi: 10.1161/CIRCINTERVENTIONS.112.974493. Epub 2013 Jan 15.
• McDonald RJ, McDonald JS, Bida JP, Carter RE, Fleming CJ, Misra S, Williamson EE, Kallmes DF. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology. 2013 Apr;267(1):106-18. doi: 10.1148/radiol.12121823. Epub 2013 Jan 29. Erratum In: Radiology. 2016 Jan;278(1):306.
• McDonald RJ, McDonald JS, Carter RE, Hartman RP, Katzberg RW, Kallmes DF, Williamson EE. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. Radiology. 2014 Dec;273(3):714-25. doi: 10.1148/radiol.14132418. Epub 2014 Sep 9.
• Nijssen EC, Nelemans PJ, Rennenberg RJ, van Ommen V, Wildberger JE. Evaluation of Safety Guidelines on the Use of Iodinated Contrast Material: Conundrum Continued. Invest Radiol. 2018 Oct;53(10):616-622. doi: 10.1097/RLI.0000000000000479.
• Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol. 2008 Aug;191(2):376-82. doi: 10.2214/AJR.07.3280.
• Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol. 2009 Mar;20(3):672-9. doi: 10.1681/ASN.2008070669. Epub 2009 Feb 25.
• Quintavalle C, Anselmi CV, De Micco F, Roscigno G, Visconti G, Golia B, Focaccio A, Ricciardelli B, Perna E, Papa L, Donnarumma E, Condorelli G, Briguori C. Neutrophil Gelatinase-Associated Lipocalin and Contrast-Induced Acute Kidney Injury. Circ Cardiovasc Interv. 2015 Sep;8(9):e002673. doi: 10.1161/CIRCINTERVENTIONS.115.002673. Erratum In: Circ Cardiovasc Interv. 2015 Oct;8(10):e000015.
• Nickolas TL, Schmidt-Ott KM, Canetta P, Forster C, Singer E, Sise M, Elger A, Maarouf O, Sola-Del Valle DA, O'Rourke M, Sherman E, Lee P, Geara A, Imus P, Guddati A, Polland A, Rahman W, Elitok S, Malik N, Giglio J, El-Sayegh S, Devarajan P, Hebbar S, Saggi SJ, Hahn B, Kettritz R, Luft FC, Barasch J. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J Am Coll Cardiol. 2012 Jan 17;59(3):246-55. doi: 10.1016/j.jacc.2011.10.854.
• Liu C, Debnath N, Mosoyan G, Chauhan K, Vasquez-Rios G, Soudant C, Menez S, Parikh CR, Coca SG. Systematic Review and Meta-Analysis of Plasma and Urine Biomarkers for CKD Outcomes. J Am Soc Nephrol. 2022 Sep;33(9):1657-1672. doi: 10.1681/ASN.2022010098. Epub 2022 Jul 20.
• Sun SQ, Zhang T, Ding D, Zhang WF, Wang XL, Sun Z, Hu LH, Qin SY, Shen LH, He B. Circulating MicroRNA-188, -30a, and -30e as Early Biomarkers for Contrast-Induced Acute Kidney Injury. J Am Heart Assoc. 2016 Aug 15;5(8):e004138. doi: 10.1161/JAHA.116.004138.
• Homolova J, Janovicova L, Konecna B, Vlkova B, Celec P, Tothova L, Babickova J. Plasma Concentrations of Extracellular DNA in Acute Kidney Injury. Diagnostics (Basel). 2020 Mar 11;10(3):152. doi: 10.3390/diagnostics10030152.
• Jancuska A, Potocarova A, Kovalcikova AG, Podracka L, Babickova J, Celec P, Tothova L. Dynamics of Plasma and Urinary Extracellular DNA in Acute Kidney Injury. Int J Mol Sci. 2022 Mar 21;23(6):3402. doi: 10.3390/ijms23063402.
• Kim SM, Cha RH, Lee JP, Kim DK, Oh KH, Joo KW, Lim CS, Kim S, Kim YS. Incidence and outcomes of contrast-induced nephropathy after computed tomography in patients with CKD: a quality improvement report. Am J Kidney Dis. 2010 Jun;55(6):1018-25. doi: 10.1053/j.ajkd.2009.10.057. Epub 2010 Jan 25.
• Wu MJ, Tsai SF. Patients with Different Stages of Chronic Kidney Disease Undergoing Intravenous Contrast-Enhanced Computed Tomography-The Incidence of Contrast-Associated Acute Kidney Injury. Diagnostics (Basel). 2022 Mar 30;12(4):864. doi: 10.3390/diagnostics12040864.
• LaBounty TM, Shah M, Raman SV, Lin FY, Berman DS, Min JK. Within-hospital and 30-day outcomes in 107,994 patients undergoing invasive coronary angiography with different low-osmolar iodinated contrast media. Am J Cardiol. 2012 Jun 1;109(11):1594-9. doi: 10.1016/j.amjcard.2012.01.380. Epub 2012 Mar 20.
• Martin-Moreno PL, Varo N, Martinez-Anso E, Martin-Calvo N, Sayon-Orea C, Bilbao JI, Garcia-Fernandez N. Comparison of Intravenous and Oral Hydration in the Prevention of Contrast-Induced Acute Kidney Injury in Low-Risk Patients: A Randomized Trial. Nephron. 2015;131(1):51-8. doi: 10.1159/000438907. Epub 2015 Aug 26.
• Faggioni M, Mehran R. Preventing Contrast-induced Renal Failure: A Guide. Interv Cardiol. 2016 Oct;11(2):98-104. doi: 10.15420/icr.2016:10:2.

Helpful Links

• OECD (2022), Computed tomography (CT) exams (indicator). doi: 10.1787/3c994537-en (Accessed on 02 February 2022).
• Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for acute kidney injury
• European Society of Urogenital Radiology's Guidelines on Contrast Agents.
• American College of Radiology - Manual on Contrast Media 2023
• Specialevejledning for Intern Medicin: Nefrologi (2018)

Study record dates

Study Major Dates

• Study Start (Actual): April 20, 2022
• Primary Completion (Estimated): March 16, 2025
• Study Completion (Estimated): March 16, 2026

Study Registration Dates

• First Submitted: February 25, 2022
• First Submitted That Met QC Criteria: March 7, 2022
• First Posted (Actual): March 17, 2022

Study Record Updates

• Last Update Posted (Actual): July 27, 2023
• Last Update Submitted That Met QC Criteria: July 24, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: Prophylaxis; Intravenous; Cardiac CT; Computed Tomography; Contrast material; Oral Hydration; IV-hydration
• Additional Relevant MeSH Terms: Pathologic Processes; Urologic Diseases; Disease Attributes; Chronic Disease; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Kidney Diseases; Renal Insufficiency, Chronic; Wounds and Injuries; Kidney Failure, Chronic; Renal Insufficiency; Acute Kidney Injury
• Other Study ID Numbers: S-20210126; Danish Data Protection Act (Registry Identifier: 21/66779)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Individual participant data (IPD) will be available in an anonymous format in accordance with the legislations from GDPR upon reasonable request.

Rules for external researchers to apply for and access data will be laid out towards the end of the study.

• IPD Sharing Time Frame: TBA
• IPD Sharing Access Criteria: TBA
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; ICF; ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No